Tempest Therapeutics, Inc. (TPST)
NASDAQ: TPST · IEX Real-Time Price · USD
3.360
+0.020 (0.60%)
Apr 16, 2024, 3:37 PM EDT - Market open

Company Description

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors.

The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.

It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.

Tempest Therapeutics, Inc.
Tempest Therapeutics logo
Country United States
Founded 2011
Industry Biotechnology
Sector Healthcare
Employees 17
CEO Stephen R. Brady J.D., LLM

Contact Details

Address:
2000 Sierra Point Parkway, Suite 400
Brisbane, California 94005
United States
Phone 415-798-8589
Website tempesttx.com

Stock Details

Ticker Symbol TPST
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001544227
CUSIP Number 87978U108
ISIN Number US87978U1088
Employer ID 45-1472564
SIC Code 2834

Key Executives

Name Position
Stephen R. Brady J.D., LLM Chief Executive Officer, President and Director
Dr. Samuel Whiting M.D., Ph.D. Executive Vice President and Chief Medical Officer
Nicholas Maestas Vice President of Strategy and Finance and Secretary
Justin Trojanowski Corporate Controller, Treasurer and Principal Accounting Officer
Lindsay Young Head of Human Resources
Dr. Sharon Sakai Ph.D., RAC Head of Regulatory and Quality

Latest SEC Filings

Date Type Title
Mar 19, 2024 S-8 Securities to be offered to employees in employee benefit plans
Mar 19, 2024 10-K Annual Report
Mar 19, 2024 8-K Current Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 9, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 8, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Nov 17, 2023 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Nov 17, 2023 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Nov 17, 2023 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments